CXCL12 deficiency promotes colorectal cancer progression and reduces anti-PD-L1 immunotherapy efficacy through MDSC regulation
Our identification of CPEB3, DDX39B, and SIDT2 as CRC revealed that CXCL12-related CRC biomarkers, combined with mechanistic evidence linking CXCL12 to MDSC regulation and anti-PD-L1 resistance, provides a novel framework for understanding immunotherapy failure in CRC. These findings might aid in establishing clinical CRC treatment strategies guiding the development of CXCL12-targeted combination strategies to overcome anti-PD-L1 resistance and improve CRC immunotherapy outcomes.
Authors
- Xiuqin An
- Junni Wei
- Heping Zhao (ORCID: https://orcid.org/0000-0002-7746-575X)
- Yuhan Wang (ORCID: https://orcid.org/0009-0000-6809-6780)
- Yunfeng Liu (ORCID: https://orcid.org/0000-0003-3089-8862)
- Xing Chen (ORCID: https://orcid.org/0000-0002-9087-4232)
- Xiaonan Wang (ORCID: https://orcid.org/0000-0003-3759-778X)
- Jie Zhang (ORCID: https://orcid.org/0000-0002-4327-3362)
- Yao Tian (ORCID: https://orcid.org/0000-0001-8745-8898)
- Sainan Liu (ORCID: https://orcid.org/0000-0002-6505-8196)
- Lijun Jiang (ORCID: https://orcid.org/0000-0002-7391-6322)
- Meimei Wei
Institutions
- Shanxi Medical University (CN)
- First Hospital of Shanxi Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1186/s12967-025-07309-1
- Primary Topic
- Chemokine receptors and signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00